SABS SAB Biotherapeutics Inc
Price (delayed)
$1.25
Market cap
$11.61M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.68
Enterprise value
$7.38M
Highlights
The EPS has soared by 52% YoY and by 42% QoQ
SAB Biotherapeutics's net income has increased by 25% QoQ and by 19% YoY
The company's debt fell by 21% YoY but it rose by 3.3% QoQ
SAB Biotherapeutics's equity has shrunk by 55% YoY and by 30% QoQ
The quick ratio has plunged by 50% YoY and by 25% from the previous quarter
Key stats
What are the main financial stats of SABS
Market
Valuations
Earnings
Shares outstanding
9.29M
Market cap
$11.61M
Enterprise value
$7.38M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.44
Price to sales (P/S)
8.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.58
Revenue
$1.32M
Gross profit
$1.32M
Operating income
-$42.91M
Net income
-$34.11M
EBIT
-$33.79M
EBITDA
-$28.99M
Free cash flow
-$34.63M
Per share
Balance sheet
Liquidity
EPS
-$3.68
EPS diluted
-$3.68
Free cash flow per share
-$3.74
Book value per share
$2.81
Revenue per share
$0.14
TBVPS
$4.77
Total assets
$44.2M
Total liabilities
$18.23M
Debt
$4.67M
Equity
$25.97M
Working capital
$15.81M
Debt to equity
0.18
Current ratio
2.98
Quick ratio
2.6
Net debt/EBITDA
0.15
Margins
Efficiency
Dividend
EBITDA margin
-2,192.5%
Gross margin
100%
Net margin
-2,579%
Operating margin
-3,244.9%
Return on assets
-59%
Return on equity
-84.3%
Return on invested capital
-79.9%
Return on capital employed
-93.3%
Return on sales
-2,554.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SABS stock price
How has the SAB Biotherapeutics stock price performed over time
Intraday
1.61%
1 week
-18.3%
1 month
-26.9%
1 year
-72.22%
YTD
-67.05%
QTD
-8.09%
Financial performance
How have SAB Biotherapeutics's revenue and profit performed over time
Revenue
$1.32M
Gross profit
$1.32M
Operating income
-$42.91M
Net income
-$34.11M
Gross margin
100%
Net margin
-2,579%
The operating margin has dropped by 91% year-on-year but it rose by 5% since the previous quarter
SAB Biotherapeutics's gross profit has decreased by 41% YoY and by 13% QoQ
SAB Biotherapeutics's revenue has decreased by 41% YoY and by 13% QoQ
The company's net margin fell by 37% YoY but it rose by 14% QoQ
Growth
What is SAB Biotherapeutics's growth rate over time
Valuation
What is SAB Biotherapeutics stock price valuation
P/E
N/A
P/B
0.44
P/S
8.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.58
The EPS has soared by 52% YoY and by 42% QoQ
SAB Biotherapeutics's equity has shrunk by 55% YoY and by 30% QoQ
The P/B is 51% below the last 4 quarters average of 0.9
The P/S is 50% below the last 4 quarters average of 17.4
SAB Biotherapeutics's revenue has decreased by 41% YoY and by 13% QoQ
Efficiency
How efficient is SAB Biotherapeutics business performance
SAB Biotherapeutics's ROIC has soared by 59% YoY and by 29% from the previous quarter
The ROE has grown by 42% YoY and by 11% from the previous quarter
The ROS has decreased by 37% YoY but it has increased by 15% QoQ
SABS's ROA is up by 33% YoY and by 12% from the previous quarter
Dividends
What is SABS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SABS.
Financial health
How did SAB Biotherapeutics financials performed over time
The company's total assets is 142% higher than its total liabilities
The quick ratio has plunged by 50% YoY and by 25% from the previous quarter
The company's total assets fell by 47% YoY and by 18% QoQ
The company's debt is 82% lower than its equity
SABS's debt to equity has soared by 80% year-on-year and by 50% since the previous quarter
SAB Biotherapeutics's equity has shrunk by 55% YoY and by 30% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.